Optimal Pandemic Influenza Vaccine Allocation Strategies for the Canadian Population

Tuite, Ashleigh R.; Fisman, David N.; Kwong, Jeffrey C.; Greer, Amy L.
May 2010
PLoS ONE;2010, Vol. 5 Issue 5, p1
Academic Journal
Background: The world is currently confronting the first influenza pandemic of the 21st century. Influenza vaccination is an effective preventive measure, but the unique epidemiological features of swine-origin influenza A (H1N1) (pH1N1) introduce uncertainty as to the best strategy for prioritization of vaccine allocation. We sought to determine optimal prioritization of vaccine distribution among different age and risk groups within the Canadian population, to minimize influenza-attributable morbidity and mortality. Methodology/Principal Findings: We developed a deterministic, age-structured compartmental model of influenza transmission, with key parameter values estimated from data collected during the initial phase of the epidemic in Ontario, Canada. We examined the effect of different vaccination strategies on attack rates, hospitalizations, intensive care unit admissions, and mortality. In all scenarios, prioritization of high-risk individuals (those with underlying chronic conditions and pregnant women), regardless of age, markedly decreased the frequency of severe outcomes. When individuals with underlying medical conditions were not prioritized and an age group-based approach was used, preferential vaccination of age groups at increased risk of severe outcomes following infection generally resulted in decreased mortality compared to targeting vaccine to age groups with higher transmission, at a cost of higher population-level attack rates. All simulations were sensitive to the timing of the epidemic peak in relation to vaccine availability, with vaccination having the greatest impact when it was implemented well in advance of the epidemic peak. Conclusions/Significance: Our model simulations suggest that vaccine should be allocated to high-risk groups, regardless of age, followed by age groups at increased risk of severe outcomes. Vaccination may significantly reduce influenza-attributable morbidity and mortality, but the benefits are dependent on epidemic dynamics, time for program roll-out, and vaccine uptake.


Related Articles

  • Influenza-Associated Intensive-Care Unit Admissions and Deaths - California, September 29, 2013-January 18, 2014. Ayscue, Patrick; Murray, Erin; Uyeki, Timothy; Zipprich, Jennifer; Harriman, Kathleen; Salibay, Catheryn; Kang, Monica; Luu, Annie; Glenn-Finer, Rose; Watt, James; Glaser, Carol; Louie, Janice // MMWR Recommendations & Reports;2/21/2014, Vol. 63 Issue 7, p143 

    The article presents a report which describes the characteristics of intensive-care unit (ICU) and fata influenza cases in California from September 29, 2013 to January 18, 2014. It is inferred that 405 cases of severe influenza reported to the California Department of Public Health were caused...

  • CAF01 Potentiates Immune Responses and Efficacy of an Inactivated Influenza Vaccine in Ferrets. Martel, Cyril Jean-Marie; Agger, Else Marie; Poulsen, Julie Juul; Jensen, Trine Hammer; Andresen, Lars; Christensen, Dennis; Nielsen, Lars Peter; Blixenkrone-Møller, Merete; Andersen, Peter; Aasted, Bent // PLoS ONE;2011, Vol. 6 Issue 8, p1 

    Trivalent inactivated vaccines (TIV) against influenza are given to 350 million people every year. Most of these are nonadjuvanted vaccines whose immunogenicity and protective efficacy are considered suboptimal. Commercially available non-adjuvanted TIV are known to elicit mainly a humoral...

  • Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination. Mulley, William R; Visvanathan, Kumar; Hurt, Aeron C; Brown, Fiona G; Polkinghorne, Kevan R; Mastorakos, Tasoula; Lewicki, Michelle C; Stuart, Rhonda L; Tan, Sven-Jean; Chean, Roy; Kerr, Peter G; Kanellis, John // Kidney International;Jul2012, Vol. 82 Issue 2, p212 

    In late 2009 transplant organizations recommended that kidney recipients be vaccinated for pandemic H1N1 influenza (pH1N1); however, the vaccine efficacy was unknown. We had offered a monovalent non-adjuvanted pH1N1 vaccine to transplant recipients. Here we compared the pre- and post-vaccination...

  • Editorial. Ramírez, Armando Torres // Ginecologia y Obstetricia de Mexico;jan2010, Vol. 78 Issue 1, p3 

    No abstract available.

  • Adjuvant effect of docetaxel on the immune responses to influenza A H1N1 vaccine in mice. Jian Chen; Lin Yuan; Qing Fan; Fei Su; Yu Chen; Songhua Hu // BMC Immunology;2012, Vol. 13 Issue 1, p36 

    Background: Vaccination remains one of the most effective approaches to prevent the spread of infectious diseases. Immune responses to vaccination can be enhanced by inclusion of adjuvant in a vaccine. Paclitaxel extracted from the bark of the Pacific yew tree Taxus brevifola was previously...

  • Toward Effective Vaccine Deployment: A Systematic Study. Liu, Jiming; Xia, Shang // Journal of Medical Systems;Oct2011, Vol. 35 Issue 5, p1153 

    Vaccination is a commonly-used epidemic control strategy based on direct antiviral immunization and indirect reduction of virus transmissibility. There exist three factors related to the efficacy of vaccine deployment; they are: (1) vaccine coverage, (2) releasing time, and (3) deployment...

  • 2009 Pandemic Influenza A Virus Subtype H1N1 in Morocco, 2009–2010: Epidemiology, Transmissibility, and Factors Associated With Fatal Cases. Barakat, Amal; Ihazmad, Hassan; El Falaki, Fatima; Tempia, Stefano; Cherkaoui, Imad; El Aouad, Rajae // Journal of Infectious Diseases;Dec2012 Supplement 1, Vol. 206 Issue suppl_1, pS94 

    Background. Following the emergence of 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09) in the United States and Mexico in April 2009, A(H1N1)pdm09 spread rapidly all over the world. There is a dearth of information about the epidemiology of A(H1N1)pdm09 in Africa, including Morocco....

  • INFLUENZA UPDATE. O'Dowd, Adrian // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;1/15/2011, Vol. 342 Issue 7789, p134 

    The article discusses various issues concerning influenza in Great Britain. From September 5, 2010 to January 6, 2011, 50 people were reported to have died with influenza infection, 45 of which died of H1N1 and the remaining died from flu type B strain. The flu pandemic in Great Britain in 2009...

  • Influenza Vaccine to Protect Mothers and Their Babies.  // Annals of Internal Medicine;12/6/2011, Vol. 155 Issue 11, pI-52 

    An excerpt from the article "Maternal Immune Response and Neonatal Seroprotection From Single Dose of a Monovalent Nonadjuvanted 2009 Influenza A(H1N1) Vaccine. A Single-Group Trial" by V. Tsatsaris, C. Capitant, and T. Schmitz in the December 6, 2011 issue is presented.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics